Lyell Immunopharma reported a net margin of -1,128,825.00% for the quarter ended Jun 2026. These financial ratios cover 25 quarters of results from Jun 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | |||||||||||||||||||||||||
| EBT Margin | -1,774.63% | -1,780.97% | -13,300.72% | -109.15% | -2,139,533.33% | 1.33% | -89,321.54% | -224,596.30% | -209,724.00% | -403,261.54% | -1,625,200.00% | -347,415.38% | -131,000.00% | -1,783,881.82% | -764,357.14% | -548,300.00% | -226,580.00% | -2,082,800.00% | -2,103,350.00% | -1,128,825.00% | |||||
| EBIT Margin | -1,784.43% | -1,684.55% | -12,400.72% | -104.25% | -2,214,566.67% | -30.55% | -96,240.00% | -244,092.59% | -236,156.00% | -457,753.85% | -1,852,500.00% | -396,369.23% | -148,544.12% | -1,828,609.09% | -819,528.57% | -589,250.00% | -248,353.33% | -2,127,400.00% | -2,213,050.00% | -1,183,425.00% | |||||
| EBITDA Margin | -1,784.43% | -1,684.55% | -12,400.72% | -104.25% | -2,214,566.67% | -30.55% | -96,240.00% | -244,092.59% | -236,156.00% | -457,753.85% | -1,852,500.00% | -396,369.23% | -148,544.12% | -1,828,609.09% | -819,528.57% | -589,250.00% | -248,353.33% | -2,127,400.00% | -2,213,050.00% | -1,183,425.00% | |||||
| Operating Margin | -1,784.43% | -1,684.55% | -12,400.72% | -104.25% | -2,214,566.67% | -30.55% | -96,240.00% | -244,092.59% | -236,156.00% | -457,753.85% | -1,852,500.00% | -396,369.23% | -148,544.12% | -1,828,609.09% | -819,528.57% | -589,250.00% | -248,353.33% | -2,127,400.00% | -2,213,050.00% | -1,183,425.00% | |||||
| Net Margin | -1,774.63% | -1,780.97% | -13,300.72% | -109.15% | -2,139,533.33% | 1.33% | -89,321.54% | -224,596.30% | -209,724.00% | -403,261.54% | -1,625,200.00% | -347,415.38% | -131,000.00% | -1,783,881.82% | -764,357.14% | -548,300.00% | -226,580.00% | -2,082,800.00% | -2,103,350.00% | -1,128,825.00% | |||||
| FCF Margin | -1,346.32% | -1,540.79% | -10,413.20% | -144.10% | -1,329,800.00% | -92.69% | -73,453.85% | -148,496.30% | -151,524.00% | -312,769.23% | -1,407,866.67% | -294,115.38% | -103,238.24% | -429,872.73% | -785,485.71% | -432,825.00% | -190,926.67% | -542,583.33% | -1,935,100.00% | -851,875.00% | |||||
| Efficiency | |||||||||||||||||||||||||
| Assets AverageAssets Avg. | 1,214.10M | 1,162.87M | 1,099.75M | 1,046.89M | 999.47M | 957.41M | 909.01M | 857.90M | 815.17M | 772.51M | 722.12M | 674.18M | 636.68M | 555.04M | 460.33M | 407.63M | 396.71M | 374.01M | 345.34M | 330.89M | |||||
| Asset Utilization RatioAsset Util. | 0.01 | 0.01 | 0.01 | 0.04 | 0.04 | 0.09 | 0.09 | 0.06 | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Valuation | |||||||||||||||||||||||||
| Price to EarningsP/E | -72.59 | -20.93 | -16.85 | -41.30 | -28.46 | 0.00M | -10.15 | -13.16 | -7.06 | -9.40 | -11.66 | -8.22 | -7.95 | -0.96 | -2.97 | -2.99 | -9.22 | -4.21 | -11.12 | -7.28 | |||||
| Price to SalesP/S | 0.00M | 372.79 | 0.00M | 45.08 | 0.61M | 17.90 | 0.01M | 0.03M | 0.01M | 0.04M | 0.19M | 0.03M | 0.01M | 0.02M | 0.02M | 0.02M | 0.02M | 0.09M | 0.23M | 0.08M | |||||
| Price to BookP/B | 3.60 | 1.13 | 1.41 | 1.86 | 2.23 | 1.04 | 0.75 | 1.08 | 0.53 | 0.75 | 0.94 | 0.66 | 0.67 | 0.49 | 0.47 | 0.44 | 0.95 | 2.12 | 1.71 | 1.41 | |||||
| Enterprise Value | 2,929.96M | 437.21M | 625.47M | 955.59M | 1,178.80M | 225.85M | -23.69M | 202.52M | -205.18M | -53.54M | 42.19M | -119.99M | -86.49M | -181.81M | -142.31M | -145.68M | -6.29M | 278.90M | 213.94M | 124.63M | |||||
| EV to EBIT | -59.60 | -9.20 | -9.12 | -25.65 | -17.74 | -15.28 | 0.38 | -3.07 | 3.48 | 0.90 | -0.76 | 2.33 | 1.71 | 0.90 | 2.48 | 3.09 | 0.17 | -2.19 | -4.83 | -2.63 | |||||
| EV to EBITDA | -59.60 | -9.20 | -9.12 | -25.65 | -17.74 | -15.28 | 0.38 | -3.07 | 3.48 | 0.90 | -0.76 | 2.33 | 1.71 | 0.90 | 2.48 | 3.09 | 0.17 | -2.19 | -4.83 | -2.63 | |||||
| Market Capitalization | 3,548.88M | 1,052.01M | 1,239.39M | 1,611.16M | 1,826.93M | 866.00M | 589.08M | 798.27M | 370.25M | 492.68M | 568.49M | 371.13M | 354.06M | 188.72M | 158.86M | 131.11M | 313.33M | 526.12M | 467.97M | 328.73M | |||||
| Price to FCFP/FCF | -95.68 | -24.19 | -21.52 | -31.28 | -45.79 | -19.31 | -12.34 | -19.91 | -9.77 | -12.12 | -13.46 | -9.71 | -10.09 | -3.99 | -2.89 | -3.79 | -10.94 | -16.16 | -12.09 | -9.65 | |||||
| EV to FCF | -78.99 | -10.06 | -10.86 | -18.55 | -29.55 | -5.04 | 0.50 | -5.05 | 5.42 | 1.32 | -1.00 | 3.14 | 2.46 | 3.84 | 2.59 | 4.21 | 0.22 | -8.57 | -5.53 | -3.66 | |||||
| EV to CFO | -114.94 | -13.16 | -13.07 | -21.55 | -31.77 | -5.61 | 0.51 | -5.17 | 5.44 | 1.32 | -1.00 | 3.15 | 2.47 | 3.85 | 2.60 | 4.23 | 0.22 | -8.65 | -5.56 | -3.67 | |||||
| Return Ratios | |||||||||||||||||||||||||
| Return on Sales [ROS]ROS | -1,784.43% | -1,684.55% | -12,400.72% | -104.25% | -2,214,566.67% | -30.55% | -96,240.00% | -244,092.59% | -236,156.00% | -457,753.85% | -1,852,500.00% | -396,369.23% | -148,544.12% | -1,828,609.09% | -819,528.57% | -589,250.00% | -248,353.33% | -2,127,400.00% | -2,213,050.00% | -1,183,425.00% | |||||
| Return on Capital Employed [ROCE]ROCE | -17.90% | -19.24% | -21.53% | -20.32% | -23.18% | -20.32% | -20.61% | -25.46% | -25.93% | -33.47% | -34.80% | -35.08% | -36.00% | -71.57% | -86.04% | -96.07% | -93.99% | -83.00% | -83.11% | -88.14% | |||||
| Return on Assets [ROA]ROA | -16.91% | -18.63% | -21.39% | -20.22% | -22.71% | -18.39% | -17.67% | -21.24% | -20.91% | -28.94% | -29.67% | -29.48% | -29.98% | -60.30% | -73.74% | -82.95% | -82.58% | -68.53% | -70.91% | -74.40% |